The global histology and cytology market is estimated to grow at a significant CAGR of nearly 13.0% during the forecast period. Rising prevalence of cancer and infectious diseases have led the demand for innovations in the anatomical pathology solutions for more accurate screening and diagnosis of the condition. As a result, several companies are focusing on strategic initiatives such as mergers and acquisitions, product launches, and partnerships and collaborations to expand the range of product portfolio with innovative features that can support to increase their market share. Some key players operating in the market include Abbott Laboratories, Merck KGaA, F. Hoffman-La Roche AG, Hologic, Inc., and Becton, Dickinson, and Co. They are increasing capabilities of their histology and cytology tests to deliver complete automation, faster turnaround time, and increased throughput that will offer users with considerable flexibility to increase overall workflow efficiencies. Some crucial strategic initiatives by the market players include-
To Request a Sample of our Report on Global Histology and Cytology Market: https://www.omrglobal.com/request-sample/histology-and-cytology-market
· In March 2020, F. Hoffmann-La Roche Ltd declared the US FDA approval of CINtec PLUS Cytology. It is the first biomarker-based triage test for women whose primary results of cervical cancer screening are positive for the human papillomavirus (HPV) using cobas 4800 HPV Test. It can more facilitate clinical decisions by offering easy to understand results that will support clinicians and women to take further steps.
The Roche cobas 4800 HPV Test, used along with CINtec histology and CINtec PLUS cytology that can offer powerful support to the labs and clinicians in the US. The CINtec PLUS cytology test features dual-stain biomarker technology that enables to detect the simultaneous presence of the two biomarkers within a single cell, including Ki-67 and p16, which is linked with HPV infections. As a result, the test holds the ability to differentiate those women who are at considerable risk for cervical disease.
· In June 2019, PHC Holdings Corp. acquired Anatomical Pathology business from Thermo Fisher Scientific Inc., for nearly $1.1billion. Anatomical Pathology business of Thermo Fisher Scientific is a part of Specialty Diagnostics division, which includes instruments, consumables, and microscope slides. The portfolio covers consumables and laboratory equipment for rabbit monoclonal antibodies, histology and cytology testing, digital pathology products, and other pathology instruments.
With the acquisition of Thermo Fisher’s Anatomical Pathology business,a new stand-alone company named Epredia was established to serve comprehensive anatomical pathology solutions. This acquisition will enable to strengthen the diagnostics business of PHC Holdings Corp. by enhancing the cancer product portfolio and will leverage further growth of the business.
· In September 2018, Koninklijke Philips N.V. declared the release of Tissue Mark, a computational pathology software which is intended for the region of interest detection for a large number of molecular testing. This will support research laboratories to improve tumor estimation accuracy. Apart from offering tumor sufficiency guidance for lung cytology, lung histology, and tissue samples of colon and breast in 60 seconds, the updated TissueMark software will offer this guidance to high-grade serous carcinoma ovarian tissue and whole slide images (WSI) of adenocarcinoma prostate tissue. This update will allow TissueMark to exhibit awide-ranging portfolio of AI-powered applications. The software will leverage deep learning AI to support in the identification of prostate and ovarian tumor tissues.
(Get 15% Discount on Buying this Report)
A full Report of Global Histology and Cytology Market is Available at: https://www.omrglobal.com/industry-reports/histology-and-cytology-market
Global Histology and Cytology Market- Segmentation
By Type of Examination
· Histology
· Cytology
By Product
· Reagents and Consumables
· Instruments and Analysis Software System
By End-User
· Hospitals and Clinical Laboratories
· Academic and Research Institutes
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
